英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
soudoier查看　soudoier　在百度字典中的解释百度英翻中〔查看〕
soudoier查看　soudoier　在Google字典中的解释Google英翻中〔查看〕
soudoier查看　soudoier　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home - SOFIE
    Our vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics)
  • Who We Are - SOFIE
    We are dedicated to improving patient outcomes by developing, supplying and delivering molecular diagnostics and therapeutics (theranostics)
  • Find a Radiopharmacy - SOFIE
    SOFIE is dedicated to providing reliable, high quality radiopharmaceuticals and cutting-edge technologies
  • Network - SOFIE
    SOFIE has built a high-capacity PET radiopharmaceutical network capable of delivering large volumes of products to as many patients as possible Our product lines include FDG, Pylarify, Neuraceq, and other clinical trial products
  • SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 . . .
    SOFIE Biosciences today announced that the first patient has been dosed in its Phase 3 clinical trial evaluating [18F]FAPI-74, a fluorine-18 labeled radiopharmaceutical targeting Fibroblast Activation Protein (FAP), as a novel diagnostic for patients with Pancreatic Ductal Adenocarcinoma
  • SOFIE’s Phase 2 FAPI Study Outcomes Showcased at ASCO GI 2026 - SOFIE
    Results from SOFIE’s Phase 2 diagnostic study on [18 F]FAPI-74 PET were presented to the oncological community at the esteemed ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco January 8-10, 2026 The multi-center trial showed that [18 F]FAPI-74 PET detects FAP expression and presence of disease in cancers of the gastrointestinal tract, with high positive predictive values
  • Team - SOFIE
    Our team works alongside our Pharma and Academic partners to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease
  • SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies . . .
    It is fantastic to see that [18 F]FAPI-74 is now moving into a pivotal phase 3 study ” STUDY DESIGN AND NEXT STEPS The EOP2 meeting focused on discussing SOFIE’s Phase 2 data and resulted in alignment with the FDA on the two Phase 3 studies’ design and endpoints
  • SOFIE drives U. S. manufacture of [18F]FAPI-74 - SOFIE
    Seven SOFIE radiopharmacies now produce the FAP-targeting radiopharmaceutical, as SOFIE launches Phase 3 clinical trials and support of Pharma and Academic groups Map shows planned [18F]FAPI-74 U S Coverage for 2026 Kansas City, MO, and Houston, TX, are the latest SOFIE radiopharmacies cleared to manufacture [18F]FAPI-74, bringing the total number of sites to seven The other locations
  • SOFIE activates FAPI-GO, first [18F]FAPI-74 Phase 3 trial - SOFIE
    Another defining moment for SOFIE Biosciences! Last Friday, November 14, 2025, FAPI-GO, SOFIE’s FAPI-74 Phase 3 study in gastroesophageal cancers, officially went live! The first site, a collaboration with Helios Clinical Research and RadNet, has been activated and is ready to enroll patients SOFIE plans to activate 18 total sites across the country over the next





中文字典-英文字典  2005-2009